Technologies

Regen-COV might work before COVID exposure, trial shows: What to know about monoclonal antibodies

Monoclonal antibodies can greatly reduce hospitalization rates in people most at risk of severe COVID-19.

For the most up-to-date news and information about the coronavirus pandemic, visit the WHO and CDC websites.

Monoclonal antibody therapy for COVID-19 is available to people in the US for free who are at higher risk of severe disease in the first few days of their illness, or after they’ve been exposed to the coronavirus. The treatment — lab-made antibodies given to a person that help their immune system stop the infection from spreading — has proven to be a key tool for preventing the coronavirus from turning into severe illness. Preliminary research shows the treatment reduces risk for hospitalization or death by about 70%.

Now, early research is showing the treatment may benefit people much earlier on, before they’ve even been exposed to the coronavirus. Regeneron, one of the drug-makers of the antibody treatments, announced Monday that its drug was 81.6% effective in preventing COVID-19 in a trial period of two to eight months post-treatment. The drug in the study, which is called Regen-COV and was given to participants in a series of four injections, is the same drug as the one currently authorized for use on at-risk people who are in the early stages of COVID-19, and on some people who’ve been exposed to it.

Dr. Myron Cohen, who leads the monoclonal antibody efforts for the National Institutes of Health’s COVID Prevention Network, said in a news release Monday that the results from the drug-maker are «particularly important to those who do not respond to COVID-19 vaccines, including people who are immunocompromised.»

Regen-COV isn’t authorized yet for use in anyone who hasn’t been exposed to or is sick with COVID-19. A few monoclonal antibody therapies, including the one made by Regeneron, have emergency use authorization by the US Food and Drug Administration and should be accessible in doctors’ offices or even some state-run clinics, as seen in states such as Florida and Texas.

Importantly, monoclonal antibodies don’t replace the role of the COVID-19 vaccines in preventing hospitalization and death. According to data from August by the US Centers for Disease Control and Prevention, unvaccinated people were more than 11 times more likely to die from COVID-19 and about 6 times more likely to contract COVID-19 than fully vaccinated people.

A large number of Americans could be eligible for monoclonal antibody treatment if they test positive for COVID-19 (a smaller number would be eligible for the treatment without a positive test, and only a confirmed exposure). For example, everyone age 65 or older, people who are overweight, people with heart, liver, or kidney disease and many more would be eligible for the treatment in the early days of their symptoms.

Here’s what we know now about COVID-19 monoclonal antibodies.

What are monoclonal antibodies, and how do they work?

Monoclonal antibodies are lab-made antibodies that work by binding to bacteria, cancer cells or viruses the way natural antibodies do, stopping them from infecting more cells. The first monoclonal antibody therapy was approved more than 30 years ago and has been used for other illnesses, including the Ebola virus.

Monoclonal antibody treatments for COVID-19 are used before a person gets really sick, usually within 10 days of their first symptom, to prevent hospitalization. The treatment is only approved for people who are at risk of getting extremely sick — those who are age 65 or older and those who have «certain medical conditions,» per the FDA. The same treatment isn’t recommended for people who are already hospitalized with COVID-19.

Monoclonal antibody therapy is also authorized if an at-risk person is exposed to COVID-19, but the definition of «at-risk» in this instance, per the FDA, is a little narrower and reserved for people who are at risk because of a medical condition and unvaccinated or not fully protected by the COVID-19 vaccines because of an immunocompromising condition.

I tested positive. How do I know if I’m eligible?

If you come down with the coronavirus and are concerned about how the disease will affect you, contacting your doctor to learn your options and the best line of treatment for you is a good idea. But, in general, this specific treatment is reserved for people who are at risk for severe disease. Most people who are infected with COVID-19 will recover at home without medical help.

The people who test positive for COVID-19 and would be eligible or benefit from monoclonal antibody therapy may also be the same people who are eligible for COVID-19 vaccine boosters because of a medical condition. For those who are at risk of severe COVID-19 and would be eligible for monoclonal antibodies if they test positive (if they’re at least 12 years old and weigh at least 88 pounds) the FDA defines «at risk» under the EUA as:

All people age 65 and older.
People with obesity or those who are overweight (adults with a BMI of more than 25, and children age 12-17 who have a BMI at the 85th percentile or greater).
Pregnant people.
People with cancer.
People with chronic kidney or lung disease.
Individuals with cardiovascular disease or hypertension.
People with diabetes.
People with sickle cell disease.
Those living with neurodevelopmental disorders.
People who are immunocompromised or taking immunocompromising medication.
Those who have a «medical-related technological dependence» (such as a tracheostomy or gastrostomy).

However, the FDA stressed in a fact sheet for Eli Lilly’s treatment (another brand of monoclonal antibodies) that this isn’t a complete list, and other medical conditions or factors including race or ethnicity may also place individuals at higher risk for severe COVID-19. It also pointed to the CDC’s list of «people with certain medical conditions» for other health conditions, which includes things such as depression and Down syndrome as being high-risk conditions.

In sum: If you test positive and feel you are at risk for severe COVID-19 and might qualify for monoclonal antibodies, you should probably speak to a health care professional about them.

Does vaccine status matter?

No, people who test positive for COVID-19 and are eligible for monoclonal antibody therapy because of their age or health condition can be treated regardless of their vaccination status. That is because, while still protective, the vaccines may be less effective at preventing severe disease in some people than others.

However, being unvaccinated might make you eligible for monoclonal antibodies after an exposure to someone with COVID-19. According to the FDA’s authorization of Regen-COV for post-exposure, people eligible for post-exposure treatment must be at risk of severe COVID-19 disease, and either unvaccinated or vaccinated but immunocompromised or taking immunocompromising medications.

I qualify. How do I access the treatment?

Monoclonal antibodies are administered by IV (most commonly) or by injection, so they’re not a prescription you can easily pick up at the pharmacy. According to CNN, the infusion process takes about an hour and patients need to wait a while to be observed for side effects. If you’re at risk for severe COVID-19 and you’ve tested positive or think you have it, ask your doctor where the treatment is available.

If you live in Texas or Florida where there are state-run monoclonal antibody treatment centers, the same eligibility requirements for patients apply. In Florida, this means everyone age 12 and older who is at «high risk for severe illness» can make an appointment and find a monoclonal treatment center at one of the state’s eight locations. In Texas, there are nine antibody infusion centers across the state, but at-risk people need a referral from their doctor.

If you think you qualify for monoclonal antibody treatment but don’t have a health care provider, you can call the Combat COVID Monoclonal Antibodies Call Center at 1-877-332-6585. You can also use this link from the US Department of Health and Human Services antibody therapy finder.

Do monoclonal antibodies interfere with the coronavirus vaccines?

If you were treated with monoclonal antibodies and you haven’t been vaccinated yet, you should wait 90 days after your treatment to make an appointment, according to the CDC. This recommendation is until more is known about how the antibody response from the treatment affects the immune response from getting vaccinated.

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Technologies

Stay Informed About Your Flights This Holiday Season With Your iPhone’s Tracker

Your iPhone is hiding a flight tracker. Here’s how it works.

Thanksgiving is only a few short weeks away and if you plan on flying during the holiday season, keeping up-to-date on changes to your flights is crucial. Airports can be hectic during any holiday, but with the government shutdown continuing, flights are liable to change or be cancelled more often.

Luckily, it’s never been easier to get up-to-date information about your flight. For starters, your airline probably has an app, and if not, you can check its website. If you’re in a hurry, you can Google the flight number. Or you can just use your iPhone’s built-in flight tracker that’s sneakily tucked away.

That’s right: Your iPhone has a flight tracker that you may have never known about. It’s there for when it’s needed. Below, we’ll show you have to access it in not one, but two places, so you never have to go hunting for your flight info elsewhere again.

Don’t miss any of our unbiased tech content and lab-based reviews. Add CNET as a preferred Google source on Chrome.

For more on the iPhone, check out everything Apple announced at WWDC 2025.

How to track your flight via iMessage

Before we start, there are a few prerequisites you must meet:

Make sure iMessage is enabled (it doesn’t work with SMS/MMS).
You’ll need your flight number somewhere in your text messages, whether you’ve sent that information to someone (even yourself) or it’s been sent to you.
The flight number must be sent in this format: [Airline] [Flight number], for example, American Airlines 9707.

Launch the native Messages app on your iPhone and open the text message thread that contains your flight information. You’ll know the flight tracker feature works when the text with the flight information appears underlined, which means it’s actionable and you can tap on it.

If your flight is still several months away or it’s already passed, you might see a message that says, «Flight information unavailable.» You might also see another flight that’s not yours because airlines recycle flight numbers.

You can check your flight status from Spotlight Search, too

If getting your flight information from Messages wasn’t easy enough, you can also grab the details right from your iPhone’s home screen by swiping down and adding your flight number into Spotlight Search. Even better, this works with Spotlight Search on your Mac computer, too.

How to access the hidden flight tracker

Although the airline name/flight number format highlighted above is the best way to go, there are other texting options that will lead you to the same result. So let’s say we stick with American Airlines 9707, other options that may bring up the flight tracker include:

AmericanAirlines9707 (no spaces)
AmericanAirlines 9707 (only one space)
AA9707 (airline name is abbreviated and no space)
AA 9707 (abbreviated and space)

I would suggest you keep the airline name spelled out completely and add a space between the two pieces of information — like in the previous section — because for some airlines, these alternative options may not work.

Real-time flight tracking

Once everything is set, tap on the flight information in your text messages. If the feature works correctly, you should see the following two options appear in a quick-action menu:

Preview Flight: View the flight’s details. Tap this to view more information about the flight.
Copy Flight Code: Copy the flight code to your clipboard (in case you want to send your flight details to someone else via text or email).

If you select Preview Flight, at the top of the window, you’ll see the best part of this feature: a real-time flight tracker map. A line will connect the two destinations, and a tiny airplane will move between them, indicating where the flight is at that exact moment.

Underneath the map, you’ll see important flight information:

Airline name and flight number
Flight status (arriving on time, delayed, canceled, etc.)
Terminal and gate numbers (for arrival and departure)
Arrival and departure time
Flight duration
Baggage claim (the number of the baggage carousel)

If you swipe left on the bottom half of the flight tracker, you can switch between flights, but only if there’s a return flight.

For more travel tips, don’t miss our test on whether AI can help you fly more sustainably.

Technologies

How to Get Verizon’s New Internet Plan for Just $25 Per Month

Technologies

This $20K Humanoid Robot Promises to Tidy Your Home. But There Are Strings Attached

The new Neo robot from 1X is designed to do chores. It’ll need help from you — and from folks behind the curtain.

It stands 5 feet, 6 inches tall, weighs about as much as a golden retriever and costs near the price of a brand-new budget car.

This is Neo, the humanoid robot. It’s billed as a personal assistant you can talk to and eventually rely on to take care of everyday tasks, such as loading the dishwasher and folding laundry.

Neo doesn’t work cheap. It’ll cost you $20,000. And even then, you’ll still have to train this new home bot, and possibly need a remote assist as well.

If that sounds enticing, preorders are now open (for a mere $200 down). You’ll be signing up as an early adopter for what Neo’s maker, a California-based company called 1X, is calling a «consumer-ready humanoid.» That’s opposed to other humanoids under development from the likes of Tesla and Figure, which are, for the moment at least, more focused on factory environments.

Neo is a whole order of magnitude different from robot vacuums like those from Roomba, Eufy and Ecovacs, and embodies a long-running sci-fi fantasy of robot maids and butlers doing chores and picking up after us. If this is the future, read on for more of what’s in store.

Don’t miss any of our unbiased tech content and lab-based reviews. Add CNET as a preferred Google source.

What the Neo robot can do around the house

The pitch from 1X is that Neo can do all manner of household chores: fold laundry, run a vacuum, tidy shelves, bring in the groceries. It can open doors, climb stairs and even act as a home entertainment system.

Neo appears to move smoothly, with a soft, almost human-like gait, thanks to 1X’s tendon-driven motor system that gives it gentle motion and impressive strength. The company says it can lift up to 154 pounds and carry 55 pounds, but it is quieter than a refrigerator. It’s covered in soft materials and neutral colors, making it look less intimidating than metallic prototypes from other companies.

The company says Neo has a 4-hour runtime. Its hands are IP68-rated, meaning they’re submersible in water. It can connect via Wi-Fi, Bluetooth and 5G. For conversation, it has a built-in LLM, the same sort of AI technology that powers ChatGPT and Gemini.

The primary way to control the Neo robot will be by speaking to it, just as if it were a person in your home.

Still, Neo’s usefulness today depends heavily on how you define useful. The Wall Street Journal’s Joanna Stern got an up-close look at Neo at 1X’s headquarters and found that, at least for now, it’s largely teleoperated, meaning a human often operates it remotely using a virtual-reality headset and controllers.

«I didn’t see Neo do anything autonomously, although the company did share a video of Neo opening a door on its own,» Stern wrote last week.

1X CEO Bernt Børnich told her that Neo will do most things autonomously in 2026, though he also acknowledged that the quality «may lag at first.»

The company’s FAQ says that for any chore request Neo doesn’t know how to accomplish, «you can schedule a 1X Expert to guide it» to help the robot «learn while getting the job done.»

What you need to know about Neo and privacy

Part of what early adopters are signing up for is to let Neo learn from their environment so that future versions can operate more independently.

That learning process raises privacy and trust questions. The robot uses a mix of visual, audio and contextual intelligence — meaning it can see, hear and remember interactions with users throughout their homes.

«If you buy this product, it is because you’re OK with that social contract,» Børnich told the Journal. «It’s less about Neo instantly doing your chores and more about you helping Neo learn to do them safely and effectively.»

Neo’s reliance on human operation behind the scenes prompted a response from John Carmack, a computer industry luminary known for his work with VR systems and the lead programmer of classic video games including Doom and Quake.

«Companies selling the dream of autonomous household humanoid robots today would be better off embracing reality and selling ‘remote operated household help’,» he wrote in a post on the X social network (formerly Twitter) on Monday.

1X says it’s taking steps to protect your privacy: Neo listens only when it recognizes it’s being addressed, and its cameras will blur out humans. You can restrict Neo from entering or viewing specific areas of your home, and the robot will never be teleoperated without owner approval, the company says.

But inviting an AI-equipped humanoid to observe your home life isn’t a small step.

The first units will ship to customers in the US in 2026. There is a $499 monthly subscription alternative to the $20,000 full-purchase price, though that will be available at an unspecified later date. A broader international rollout is promised for 2027.

Neo’s got a long road ahead of it to live up to the expectations set by Rosie the Robot in The Jetsons way back when. But this is no Hanna-Barbera cartoon. What we’re seeing now is a much more tangible harbinger of change.